

HEAD AND NECK

Sponsor/ Protocol ID	clinicaltrials.gov Identifier (NCTxxx)	Study Title	Phase	Name of PI (Hospital)	Study Manager (Hospital)	Study Coordinator (Hospital)	Extension MUHC: 514-934-1934 JGH: 514-340-8222	Comments
Advanced Head and Neck								
1 RTOG 0920	NCT00956007	A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for locally-advanced resected Head and Neck Cancer	3	Khalil Sultanem (JGH) George Shenouda (MUHC)		Marianna Perna (MUHC) Cindy Rousseau (JGH)	43191 (MUHC) 25098 (JGH)	
Nasopharyngeal								
2 RTOG HN001	NCT02135042	Randomized phase II and phase III studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein Barr Virus (EBV) deoxyribonucleic acid (DNA)	2/3	Khalil Sultanem (JGH) George Shenouda (MUHC)		Marianna Perna (MUHC) Cindy Rousseau (JGH)	43191 (MUHC) 25098 (JGH)	
Oropharyngeal								
3 Lawson Health Research D419LC0001 ORATOR	NCT01590355	A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)	2	Michael Hier (JGH)	Adele Cascini (JGH)	Sabrina Cesare (JGH)	24301 (JGH)	
4 RCN		Marching Ahead: Imaging Biomarkers, a new revolution in patient management and care for Human Papilloma Virus (HPV) Positive Oropharyngeal Cancer		Jeffrey Chankowsky (MUHC)				
Squamous Cell (HNSCC)								
5 AstraZeneca KESTREL D419LC00001	NCT02369874	Study of MEDI4736 with or without Tremelimumab versus standard of care in recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	3	Nathaniel Bouganim (MUHC)	Penny Chipman (MUHC)	Marie-Claude Joncas (MUHC)	42560 (MUHC)	
6 MUHC		FDG Positron Emission Tomography (PET) for Early Detection of Response to Chemoradiotherapy (CRT) in Head and Neck Squamous Cell Carcinoma (HNSCC)		Anthony Zeitouni (MUHC)				
7 JGH		Lung cancer surveillance for head and neck patients: A prospective randomized study		Michael Hier (JGH)			25387 (JGH)	Agulnik (resp) and Forghani (radiology)

8	RTOG 3501	NCT01711658	TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation	2	George Shenouda (MUHC)		Marianna Perna (MUHC)	43191 (MUHC)	
9	RCN		Spectral dual energy CT and textural radiogenomic analysis for optimal tumor delineation, patient staging, and biomarker for head and neck squamous cell carcinoma		Reza Forghani (JGH)	assistant: Maryam Bayat	Ayat Salman	ayat.salman@mail.mcgill.ca	
Laryngeal									
Nasal Cavity									
Oral									
10	JGH		Phase II study of peri-operative brachytherapy +/- intensity modulated radiotherapy (IMRT) with or without chemotherapy for carcinoma of the oral tongue	2	Boris Bahoric (JGH)		Cindy Rousseau (JGH)	25098 (JGH)	surgeons Hier and Black
Paranasal Sinus									
Parathyroid									
Salivary Gland									
11	RTOG	NCT01220583	A randomized phase II/phase III study of adjuvant concurrent radiation and chemotherapy versus radiation alone in resected high-risk malignant salivary gland tumors	2/3	George Shenouda (MUHC)		Marianna Perna (MUHC)	43191 (MUHC)	
Thyroid									
12			Developing and Implementing an Interdisciplinary Team-Based Approach for Patients with a Suspected or Confirmed Thyroid Cancer (ITCA-ThyCa)		Anthony Zeitouni (MUHC)				